Thyrocare Technologies Concall was today at 12:00 PM.
Here are key highlights of the Conference Call 😀
@amitgupta0310 @MarketScientist @MashraniVivek
Here are key highlights of the Conference Call 😀
@amitgupta0310 @MarketScientist @MashraniVivek
Business Updates:
• EBIDTA margins improved, significant growth from COVID.
• Non - Covid business is back to pre-covid levels.
COVID test:
• RTPCR tests in Q2 ~ 2.7 Lac
• Antibody tests reported in Q2
• Pathology Volumes increased by 83% in Q2
• EBIDTA margins improved, significant growth from COVID.
• Non - Covid business is back to pre-covid levels.
COVID test:
• RTPCR tests in Q2 ~ 2.7 Lac
• Antibody tests reported in Q2
• Pathology Volumes increased by 83% in Q2
• Added manpower in the operational end
• In Q2 almost 40% of the business is from Covid
• As the industry open up, there can be more demand of antibody test.
• There would be no complexity in serving the operational aspect of working with open up in the economy
• In Q2 almost 40% of the business is from Covid
• As the industry open up, there can be more demand of antibody test.
• There would be no complexity in serving the operational aspect of working with open up in the economy
Nueclear Business:
• Topline has increased.
• Most of the centers are at breakeven.
• Pre-covid level many of the center has atleast reached to covid.
• Post covid management expect to atleast generate cash profit from most of the center.
• Topline has increased.
• Most of the centers are at breakeven.
• Pre-covid level many of the center has atleast reached to covid.
• Post covid management expect to atleast generate cash profit from most of the center.
COVID:
Covid check up has only been started from June month, and most of the checking has been to the institutional companies such as Infy, Tata, Reliance, while this is expected to remain continue.
Company is no doing Covid Antigen. COVID includes RTGR test and Antibody test
Covid check up has only been started from June month, and most of the checking has been to the institutional companies such as Infy, Tata, Reliance, while this is expected to remain continue.
Company is no doing Covid Antigen. COVID includes RTGR test and Antibody test
Delhi Center Facility:
• Started testing facility and commercialized
• Planning to expand in nearby cities and to increase zonal facility expansion in Delhi
• Achieved the minimum volume capacity. Adding manpower on growth side.
• With expansion profitability will be achieved
• Started testing facility and commercialized
• Planning to expand in nearby cities and to increase zonal facility expansion in Delhi
• Achieved the minimum volume capacity. Adding manpower on growth side.
• With expansion profitability will be achieved
Post COVID:
• Mgmt do expect that wellness will be more emphasized due to pandemic. People are now becoming more focus on their wellness.
• There is increase in expectation of wellness need not only for covid, but for other test as well post - covid
• Mgmt do expect that wellness will be more emphasized due to pandemic. People are now becoming more focus on their wellness.
• There is increase in expectation of wellness need not only for covid, but for other test as well post - covid
Air connectivity for logistics: March and April was very much challenging. Business was stand still.
• Now the company is able to carry on the logistics. With opening up of flights, problems have reduced to much extent.
• Now the company is able to carry on the logistics. With opening up of flights, problems have reduced to much extent.
Franchise:
• If the company want to expand fast, there can be stupendous growth in country like India.
• Company is also increasing its focus towards franchise business, and in discussion with channel partner
Thryo app- Anyone can have their test done. Seeing good growth here
• If the company want to expand fast, there can be stupendous growth in country like India.
• Company is also increasing its focus towards franchise business, and in discussion with channel partner
Thryo app- Anyone can have their test done. Seeing good growth here
• Increasing in focus on expanding in different zonal capacity.
• Expansion now would be more on the expansion in the near by established test center.
Average Price of Product:
Non Covid:
• Average price of 1700 for non covid business.
• Expansion now would be more on the expansion in the near by established test center.
Average Price of Product:
Non Covid:
• Average price of 1700 for non covid business.
Covid:
• Covid in range of 450 Rs
• Prices are regulated by govt. Prices are decreasing every 15 day.
• Avg. Covid realization in the last quarter is not a benchmark.
• Prices are reduced from 650 to Rs 450 and may reduce further too.
• Profit margins are still maintained.
• Covid in range of 450 Rs
• Prices are regulated by govt. Prices are decreasing every 15 day.
• Avg. Covid realization in the last quarter is not a benchmark.
• Prices are reduced from 650 to Rs 450 and may reduce further too.
• Profit margins are still maintained.
Testing:
• Consciousness and DNA testing has gone up
• There has been increase in demand for Consciousness is increasing
• Genetical testing and neonatel share is very small as a share.
• This won't be major contributor in near future, with increasing share in few years.
• Consciousness and DNA testing has gone up
• There has been increase in demand for Consciousness is increasing
• Genetical testing and neonatel share is very small as a share.
• This won't be major contributor in near future, with increasing share in few years.
Collection Center:
• Due to lockdown, collection center has been standstill but now with opening up focus back on track
• Opening of collection center was few.
• This is one of the future growth areas.
• On the longer term horizon company expect to double the collection share
• Due to lockdown, collection center has been standstill but now with opening up focus back on track
• Opening of collection center was few.
• This is one of the future growth areas.
• On the longer term horizon company expect to double the collection share
Dr. Velumani:
•Genetics and Neonatal will be not be huge opportunity but for now there is no such volume growth
•Diagnostics and Wellness is the only sector which will be having good growth
• Pricing disruption will be there but with volume growth
• Expansion will be on focus
•Genetics and Neonatal will be not be huge opportunity but for now there is no such volume growth
•Diagnostics and Wellness is the only sector which will be having good growth
• Pricing disruption will be there but with volume growth
• Expansion will be on focus
Conclusion:
• Pricing disruption may impact the margins. However how the volume pace out will be a good look.
• Post covid, change in demographics of wellness consumption is good watch out.
• Price realization of covid may decrease but with increase in volume.
• Pricing disruption may impact the margins. However how the volume pace out will be a good look.
• Post covid, change in demographics of wellness consumption is good watch out.
• Price realization of covid may decrease but with increase in volume.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
